TRANSLATING A DEEP
EXPERTISE IN GROWTH
FACTOR BIOLOGY INTO
INNOVATIVE THERAPIES
Restoring organ function Read more
Modulating growth
factor pathways to
repair tissue
structures
Restoring organ function Read more
Building Agomab
to treat fibrotic
related diseases
Restoring organ function Read more

Modulating growth factor signaling through precise and novel treatments

Our goal is to preserve and restore organ function in a range of acute and chronic conditions associated with tissue injury, inflammation, fibrosis and degeneration.
About Us

Follow us on our mission to treat fibrosis and restore organ function in multiple therapeutic areas

News & Events
PR

Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114M

July 2022

PR

Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1

January 2022

“We are determined to improve the lives of patients through innovation. With a broad European footprint, we have built a leading company that combines transformative science with the commitment and passion of our experienced team, partners, and investors.”

-

Tim Knotnerus, Chief Executive Officer